Compugen Ltd. is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics and therapeutic targets to address unmet medical needs in the fields of oncology, immunology, and autoimmune diseases. The company's proprietary computational discovery platforms are designed to identify novel drug targets and develop first-in-class therapeutics. Compugen's lead product candidate, COM701, is a first-in-class immuno-oncology therapeutic antibody currently in Phase 1 clinical development for the treatment of solid tumors. The company is also developing a pipeline of therapeutic candidates based on its computational discovery platforms, including immuno-oncology and autoimmune disease therapeutics.